Biohaven Pharma
About Biohaven Pharma
220 articles with Biohaven Pharma
-
Biohaven Receives Notice Of Allowance From U.S. Patent And Trademark Office On Patent Application For Glutamate Modulating Prodrugs
7/13/2017
-
Biohaven's BHV-5000 Receives Orphan Drug Designation From The FDA In Rett Syndrome
7/6/2017
-
Biohaven Added to Russell Microcap Index
6/26/2017
-
Biohaven Broadens Senior Leadership Team With Veteran Pharma Executives
6/22/2017
-
Biohaven Reports First Quarter 2017 Financial and Business Results
6/16/2017
-
Biohaven Completes Enrollment In Spinocerebellar Ataxia Clinical Trial With Trigriluzole
5/30/2017
-
Biohaven's Trigriluzole Receives Fast Track Designation From U.S. FDA
5/15/2017
-
Biohaven Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
5/15/2017
-
Biohaven Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares
5/12/2017
-
Portage Biotech's Holding In Biohaven
5/9/2017
-
Biohaven Announces Pricing of its Initial Public Offering of Common Shares
5/4/2017
-
Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC, Bristol-Myers Squibb Drugs
4/11/2017
-
Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board
3/8/2017
-
Biohaven Closes Second Tranche Of Private Placement And Appoints Two New Directors To Board
3/7/2017
-
Biohaven Enrolls First Patient In Pivotal Trial Of BHV-4157 In Patients With Hereditary Spinocerebellar Ataxia
12/22/2016
-
Biohaven' BHV-0223 Is Granted Orphan Drug Designation In The Treatment Of Amyotrophic Lateral Sclerosis
12/9/2016
-
Biohaven Announces Orphan Drug Designation Request Granted For Bhv-0223 In The Treatment Of Amyotrophic Lateral Sclerosis ("Als")
12/8/2016
-
Biohaven Secures $80 Million In Oversubscribed Private Financing To Advance Phase 3 Clinical Trials
11/1/2016
-
Biohaven Licenses Rights From Rutgers University To Develop And Commercialize Glutamate Modulating Agents In Cancer Treatment
10/3/2016
-
Biohaven Commences Clinical Testing Of BHV-4157
7/20/2016